Benjamin L. Ebert is President and CEO of Dana-Farber Cancer Institute, Director of Dana-Farber/Harvard Cancer Center, and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, he served as Chair of the Department of Medical Oncology from 2017 to 2024. He leads Dana-Farber’s clinical, research, and academic programs, fostering translational science and innovation in cancer care. Dr. Ebert also serves on the Board of Directors for the Broad Institute and Break Through Cancer.
During Ebert’s tenure, Dana-Farber has advanced major institutional priorities, including the scaling of cross-disease translational programs, expansion of cellular therapy and immuno-oncology platforms, and increased participation in multi-center research initiatives such as Break Through Cancer. He has overseen investments in data science, genomics, and novel therapeutic development, while supporting workforce development, mentorship, and sustainable research infrastructure. These efforts have strengthened Dana-Farber’s capacity to deliver practice-changing discoveries and maintain its global leadership in cancer research and care.
Dr. Ebert is an internationally recognized physician-scientist whose laboratory focuses on the molecular basis and treatment of hematologic malignancies, particularly myelodysplastic syndromes and clonal hematopoiesis. His research includes groundbreaking work on lenalidomide and drug-induced protein degradation. He is an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, and other prestigious scientific societies. Dr. Ebert has received numerous awards, including the William Dameshek Prize, the Meyenburg Prize, and the Sjöberg Prize, and is widely acknowledged for his mentorship and contributions to cancer research.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations.
